Proteolysis Targeting Chimeras PROTAC Therapy For Lung Cancer [Yahoo! Finance]
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Delhi, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Global Proteolysis Targeting Chimeras PROTAC Therapy Clinical Trials Insight & Market Opportunity Report Highlights: First PROTAC Drug Approval Expected By 2027 Insight On More Than 50 PROTAC Drugs In Clinical Trials Global PROTAC Drugs Clinical Trials Insight By Company, Country, Indication & Phase Orphan & Fast Track Designation Insight PROTAC Drugs Clinical Application & Development Outlook By Indication Current & Future Market Overview Global PROTAC Drug Market Dynamics Download Report: https://www.kuickresearch.com/ccformF.php?t=1728551968 Lung cancer remains one of the leading causes of cancer-related deaths globally, with millions of new cases diagnosed each year. Despite advances in treatment, including chemotherapy, radiation, immunotherapy, and targeted therapies, a significant number of lung cancers develop resistance to these interventions, making them difficult to treat. The emergence of Proteolysis Targeting Chi
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ARVNAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVNAccesswire
- Lost Money on Arvinas, Inc. (ARVN)? You May Have Been Affected by Fraud - Contact Levi & KorsinskyAccesswire
- Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities InvestigationAccesswire
- Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVNAccesswire
ARVN
Earnings
- 10/30/24 - Beat
ARVN
Sec Filings
- 11/19/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- ARVN's page on the SEC website